BibbInstruments

BibbInstruments Altman Z-Score

The Altman Z-Score of BibbInstruments (BIBB.SL) as of Oct 31, 2026 is 10.47. In the previous year, Altman Z-Score was 1.87 — a change of 460.53% (higher).

Altman Z-Score

10.47

YoY

460.53%

Last updated:

Altman Z-Score of BibbInstruments is 2025 10.47 . Altman Z-Score of BibbInstruments was 2024 1.87 . It decreases by 460.53% higher compared to the previous year.

The BibbInstruments Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2018
12.02 SEK
Jan 1, 2019
19.89 SEK
Jan 1, 2020
18.45 SEK
Jan 1, 2021
16.14 SEK
Jan 1, 2022
9.42 SEK
Jan 1, 2023
14.43 SEK
Jan 1, 2024
1.87 SEK
Jan 1, 2025
10.47 SEK
The BibbInstruments Altman Z-Score history
YEARAltman Z-ScoreYoY
10.47+460.53%
1.87-87.06%
14.43+53.17%
9.42-41.65%
16.14-12.49%
18.45-7.26%
19.89+65.40%
12.02-65.63%
34.99-28.62%
49.02-43.75%
87.13-58.90%
212.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Altman Z-Score of BibbInstruments is 10.47 in 2025.

On Eulerpool you can find the complete historical development of Altman Z-Score BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — BibbInstruments

All Key Metrics — BibbInstruments